Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23Andme Holding Co. (NQ: ME )

0.5925 -0.0184 (-3.01%)
Streaming Delayed Price Updated: 2:11 PM EDT, May 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about 23Andme Holding Co.

< Previous 1 2 3 4 5 6 Next >
Kevin Durant Launching A SPAC That Could Target Sports Or Cryptocurrency
One of the biggest National Basketball Association stars is dipping his toes into the SPAC market, becoming the latest celebrity or athlete to atta... 
Via Benzinga
Why 23andMe Rocketed 27.9% Higher in October
The genetics upstart is acquiring a telehealth platform. 
Via The Motley Fool
November SPAC Merger Calendar: Upcoming Votes, Earnings, Stocks To Watch
The month of November shows a continued slowdown in SPAC merger deal votes, but the calendar includes several multibillion-dollar deals. SPAC merger votes can act as a catalyst,... 
Via Benzinga
Why 23andMe Stock Jumped 16% Today
An analyst calls 23andMe's 11 million sample database unique and unprecedented. 
Via The Motley Fool
Why 23andMe's Stock Is Trading Higher Tuesday
23andMe Holding Co. (NASDAQ:ME) shares are trading higher by... 
Via Benzinga
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
These 3 Unique Stocks Have Undeniable Long-Term Upside
These ideas are so unconventional that they just might work. 
Via The Motley Fool
Why 23andMe Stock Was Up More Than 9% on Tuesday
Investors may see potential in the company's proposed acquisition of telehealth company Lemonaid. 
Via The Motley Fool
Why 23andMe Stock Dropped Today
Fresh off its SPAC IPO, 23andMe is buying another company. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas... 
Via Benzinga
Why 23andMe Stock Has Jumped 16% So Far This Week
A favorable mention on CNBC lit a fire underneath the biotech's stock this week. 
Via The Motley Fool
Jim Cramer Likes CVS And 23andMe, Considers This Stock 'Too Cheap'
On CNBC’s "Mad Money Lightnin... 
Via Benzinga
51 Biggest Movers From Friday
Gainers LM Funding America, Inc. (NASDAQ: LMFA) shares jumped 38.1% to close at $4.75 on Friday after declining around 15% on Thursday. The company recently announced it... 
Via Benzinga
23andMe Stock Could Be a Big Winner If This 1 Thing Happens
It needs to make money from something bigger than just its genetic test kits. 
Via The Motley Fool
ME Stock: 6 Things to Know About 23andMe as Shares Shoot Higher Today
23andMe (ME) stock is running higher on Friday as investors pile on with heavy trading thanks to a recent interview on CNBC. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Statera BioPharma (NASDAQ:STAB) shares rose 16.9% to $3.32 during Friday's regular session. The market value of their outstanding shares is at $91.7 million.... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares moved upwards by 29.96% to $7.72 during Friday's pre-market session. The company's market cap stands at $20.8... 
Via Benzinga
22 Stocks Moving in Friday's Pre-Market Session
Gainers LM Funding America, Inc. (NASDAQ: LMFA) rose 39.5% to $4.80 in pre-market trading after declining around 15% on Thursday. The company recently announced it purchased an... 
Via Benzinga
Here's Why I Bought This Recent Genetics IPO
Despite losing millions right now, this company could have massive long-term growth potential. 
Via The Motley Fool
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
Cramer Shares His Thoughts On AppHarvest, Rio Tinto And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said 23andMe Holding Co. (NASDAQ: ME) is trading at $8 and it should be higher. He wants to get the management on... 
Via Benzinga
This Biotech Company Could Offer Nearly Unlimited Optionality
Backed by its growing genetic database, 23andMe could take its business in a number of lucrative directions. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Boston Omaha and Latch: 2 Small Caps Worth a Look
Here's what we're watching in the financials sector. 
Via The Motley Fool
2 SPACs That Look Like Bargains After Post-Earnings Drops
Many recent SPAC IPOs have been hammered, and these two could be worth a closer look. 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Aerpio Pharmaceuticals (NASDAQ:ARPO) stock increased by 25.72% to $2.59 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is... 
Via Benzinga
66 Biggest Movers From Yesterday
Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND... 
Via Benzinga
ME Stock: The Credit Suisse Call Giving 23andMe a Boost Today
23andMe (ME) stock is rising higher on Tuesday after Credit Suisse weighed in on the personal genomics and biotechnology company. 
Via InvestorPlace
48 Stocks Moving In Tuesday's Mid-Day Session
Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares jumped 93% to $$8.10 after the company received a written pre-investigational new drug (pre-IND) response from the FDA... 
Via Benzinga
Why 23andMe Stock Soared Today
It's no great secret why Credit Suisse likes 23andMe. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Benzinga's Top Ratings Upgrades, Downgrades For August 17, 2021
Upgrades For Compass Minerals International Inc (NYSE: 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.